» Articles » PMID: 39568772

Ferroptosis: Mechanisms and Therapeutic Targets

Overview
Journal MedComm (2020)
Specialty Health Services
Date 2024 Nov 21
PMID 39568772
Authors
Affiliations
Soon will be listed here.
Abstract

Ferroptosis is a nonapoptotic form of cell death characterized by iron-dependent lipid peroxidation in membrane phospholipids. Since its identification in 2012, extensive research has unveiled its involvement in the pathophysiology of numerous diseases, including cancers, neurodegenerative disorders, organ injuries, infectious diseases, autoimmune conditions, metabolic disorders, and skin diseases. Oxidizable lipids, overload iron, and compromised antioxidant systems are known as critical prerequisites for driving overwhelming lipid peroxidation, ultimately leading to plasma membrane rupture and ferroptotic cell death. However, the precise regulatory networks governing ferroptosis and ferroptosis-targeted therapy in these diseases remain largely undefined, hindering the development of pharmacological agonists and antagonists. In this review, we first elucidate core mechanisms of ferroptosis and summarize its epigenetic modifications (e.g., histone modifications, DNA methylation, noncoding RNAs, and N6-methyladenosine modification) and nonepigenetic modifications (e.g., genetic mutations, transcriptional regulation, and posttranslational modifications). We then discuss the association between ferroptosis and disease pathogenesis and explore therapeutic approaches for targeting ferroptosis. We also introduce potential clinical monitoring strategies for ferroptosis. Finally, we put forward several unresolved issues in which progress is needed to better understand ferroptosis. We hope this review will offer promise for the clinical application of ferroptosis-targeted therapies in the context of human health and disease.

Citing Articles

Anti-Inflammatory Effects of Curcumin-Based Nanoparticles Containing α-Linolenic Acid in a Model of Psoriasis In Vitro.

Serini S, Trombino S, Cassano R, Marino M, Calviello G Nutrients. 2025; 17(4).

PMID: 40005020 PMC: 11858589. DOI: 10.3390/nu17040692.


Targeting Ferroptosis in Rare Neurological Disorders Including Pediatric Conditions: Innovations and Therapeutic Challenges.

Alatawi A, Venkatesan K, Asseri K, Paulsamy P, Alqifari S, Ahmed R Biomedicines. 2025; 13(2).

PMID: 40002678 PMC: 11853599. DOI: 10.3390/biomedicines13020265.


The Emerging Scenario of Ferroptosis in Pancreatic Cancer Tumorigenesis and Treatment.

Lyu H, Kong J, Chen J, Zhang R, Xiao S, Guo D Int J Mol Sci. 2025; 25(24.

PMID: 39769097 PMC: 11727763. DOI: 10.3390/ijms252413334.


Sex and Gender Differences in Iron Chelation.

Allegra S, Comita S, Roetto A, De Francia S Biomedicines. 2025; 12(12.

PMID: 39767791 PMC: 11673655. DOI: 10.3390/biomedicines12122885.

References
1.
Shou Y, Yang L, Yang Y, Xu J . Inhibition of keratinocyte ferroptosis suppresses psoriatic inflammation. Cell Death Dis. 2021; 12(11):1009. PMC: 8551323. DOI: 10.1038/s41419-021-04284-5. View

2.
Barayeu U, Schilling D, Eid M, Xavier da Silva T, Schlicker L, Mitreska N . Hydropersulfides inhibit lipid peroxidation and ferroptosis by scavenging radicals. Nat Chem Biol. 2022; 19(1):28-37. PMC: 7613997. DOI: 10.1038/s41589-022-01145-w. View

3.
Tang J, Long G, Hu K, Xiao D, Liu S, Xiao L . Targeting USP8 Inhibits O-GlcNAcylation of SLC7A11 to Promote Ferroptosis of Hepatocellular Carcinoma via Stabilization of OGT. Adv Sci (Weinh). 2023; 10(33):e2302953. PMC: 10667802. DOI: 10.1002/advs.202302953. View

4.
Wu Z, Khodade V, Chauvin J, Rodriguez D, Toscano J, Pratt D . Hydropersulfides Inhibit Lipid Peroxidation and Protect Cells from Ferroptosis. J Am Chem Soc. 2022; 144(34):15825-15837. DOI: 10.1021/jacs.2c06804. View

5.
Greenough M, Lane D, Balez R, Targa Dias Anastacio H, Zeng Z, Ganio K . Selective ferroptosis vulnerability due to familial Alzheimer's disease presenilin mutations. Cell Death Differ. 2022; 29(11):2123-2136. PMC: 9613996. DOI: 10.1038/s41418-022-01003-1. View